Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma. - sprookjes - yvandenbroek - TriplyDB

Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.

Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.

http://www.wikidata.org/entity/Q37395951

about

Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system.Mainstreaming genetics in palliative care: barriers and suggestions for clinical genetic services.

P2860

Q36130577-83E5C3C5-2E8A-4E8E-939B-F766E0478C32 Q49843939-9407C928-09BD-4715-8F9D-9784B5761722

P2860

Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.

http://www.wikidata.org/entity/Q37395951

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Timing of referral for genetic ...... primary peritoneal carcinoma.

@en

Timing of referral for genetic ...... primary peritoneal carcinoma.

@nl

type

label

Timing of referral for genetic ...... primary peritoneal carcinoma.

@en

Timing of referral for genetic ...... primary peritoneal carcinoma.

@nl

prefLabel

Timing of referral for genetic ...... primary peritoneal carcinoma.

@en

Timing of referral for genetic ...... primary peritoneal carcinoma.

@nl

P1433

Q37395951-0ECB4280-1F9B-42E7-BF91-288CCFA890B4

P1476

Q37395951-819FFD4F-15D7-4867-B358-488EA17EC931

P2093

Q37395951-0C1623A5-64BC-4CE0-97EE-90C5FE19516E

Q37395951-2E3F057E-F9C3-4E52-A6BB-880A6EBE6AB6

Q37395951-3ECD9AD5-C66C-4BB0-B0B7-45980649CA54

Q37395951-4C5FA74B-F038-4190-B635-DB951374399C

Q37395951-5071046F-A455-4A74-9341-99B027FB50DE

Q37395951-68191A83-CD73-48E8-80A9-D427F7D2A51D

Q37395951-AE5C2A87-7955-4487-9EBD-ED5A3B34DC47

Q37395951-BB66D43D-EDFC-44DE-AF00-D84FF3998350

Q37395951-FEFF1E13-9B7F-4D8C-900B-724F78ECB51D

Q37395951-FF203F35-C02A-47C7-AD51-C1C8E3C5737E

P2860

Q37395951-0481EFB1-79EA-4FEF-8B9D-876F896B2721

Q37395951-0BE55FB9-50CA-4ECA-93B4-84E2ACC82F98

Q37395951-11DCD9AF-227B-400E-921E-90B9913C3672

Q37395951-1F368DE0-85E0-4DB6-A61A-2C32962E0230

Q37395951-2E5A7C06-A27D-40D0-BD3B-7F949D8556CF

Q37395951-3139E423-8498-4B37-83EF-55AA61696CFC

Q37395951-36F5C06A-AFBF-48D9-A7A6-C5135014CA29

Q37395951-3E131C4F-F774-4C30-BC4A-29EC6552FF65

Q37395951-4BD5E073-ACC8-4A65-BCBD-588C034B1107

Q37395951-4F810EDE-1050-47E1-8196-3F35A16CC1D0

P304

Q37395951-CB61F5FA-9EFC-4A89-99F1-00601EF1F4E1

P31

Q37395951-29E54796-8336-461C-80F7-9DDEBF00B606

P356

Q37395951-F697D10E-3869-4331-85EF-867531ACACAD

P433

Q37395951-E7506DE0-2CD9-430F-9B95-C8B5F8FD00E1

P478

Q37395951-74E857E7-2FFF-4C18-A786-A670E23C9A98

P577

Q37395951-6F34E61A-0ED9-427A-90F6-25876C3FA61E

P698

Q37395951-42420546-48DB-4C9D-99C9-E235D684D7B2

P921

Q37395951-F4C86499-4141-44AC-9D95-BEE1746645A1

P932

Q37395951-EF14F38E-FDCA-4104-B96C-432654B4A51E

P356

IGC.0B013E3182994365

P1433

International Journal of Gynecological Cancer

P1476

Timing of referral for genetic ...... primary peritoneal carcinoma.

@en

P2093

Akiva P Novetsky

http://www.w3.org/2001/XMLSchema#string

Andrea R Hagemann

http://www.w3.org/2001/XMLSchema#string

David G Mutch

http://www.w3.org/2001/XMLSchema#string

Donna B Jeffe

http://www.w3.org/2001/XMLSchema#string

Israel Zighelboim

http://www.w3.org/2001/XMLSchema#string

Kylie Smith

http://www.w3.org/2001/XMLSchema#string

L Stewart Massad

http://www.w3.org/2001/XMLSchema#string

Matthew A Powell

http://www.w3.org/2001/XMLSchema#string

Premal H Thaker

http://www.w3.org/2001/XMLSchema#string

Sheri A Babb

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer

Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21

Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece.

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Satisfaction with physician recommendation for and information about genetic counseling among breast cancer patients.

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.

P304

1016-1021

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/IGC.0B013E3182994365

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23748176

http://www.w3.org/2001/XMLSchema#string

P921

P932

3864646

http://www.w3.org/2001/XMLSchema#string